LENSAR (LENSAR) ROCE % : -20.11% (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is LENSAR ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. LENSAR's annualized ROCE % for the quarter that ended in Dec. 2023 was -20.11%.

LENSAR ROCE % Historical Data

The historical data trend for LENSAR's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LENSAR ROCE % Chart

LENSAR Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

-47.39

-37.87

-30.61

-39.50

-23.89

LENSAR Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial													-23.37	-40.38	-22.35	-13.55	-20.11

LENSAR ROCE % Calculation

LENSAR's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-12.229	/	( ( (55.844 - 11.421)	+	(69.585 - 11.632) )	/ 2 )
	=	-12.229	/	( (44.423	+	57.953)	/ 2 )
	=	-12.229	/	51.188
	=	-23.89 %

LENSAR's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	-11.844	/	( ( (70.853 - 11.011)	+	(69.585 - 11.632) )	/ 2 )
	=	-11.844	/	( ( 59.842	+	57.953 )	/ 2 )
	=	-11.844	/	58.8975
	=	-20.11 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

LENSAR (NAS:LNSR) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

LENSAR ROCE % Related Terms

Thank you for viewing the detailed overview of LENSAR's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

LENSAR (LENSAR) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » LENSAR Inc (NAS:LNSR) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

2800 Discovery Drive, Orlando, FL, USA, 32826

Website

https://www.lensar.com

LENSAR Inc is a commercial-stage medical device company focused on designing, developing and marketing a femtosecond laser system for the treatment of cataracts. The company Laser System incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency and reproducibility by providing imaging, simplified procedure planning, efficient design and precision. Its product portfolio consists of the LENSAR Laser System with Streamline IV and IntelliAxis and its associated consumable components. The consumable portion of the system consists of a disposable patient interface device, or PID, kit and a procedure license. Each procedure on each system requires the use of a PID kit.

Executives

Gary M Winer	director	C/O LENSAR, INC., 2800 DISCOVERY DRIVE, ORLANDO FL 32826
Aimee S Weisner	director	ONE EDWARDS WAY, IRVINE CA 92614
Nr-gri Partners Gp, Llc	10 percent owner	867 BOYLSTON STREET, 5TH FLOOR, #1361, BOSTON MA 02116
Nr-gri Partners, Lp	10 percent owner	867 BOYLSTON STREET, 5TH FLOOR, #1361, BOSTON MA 02116
Todd B Hammer	director, 10 percent owner	NORTH RUN CAPITAL PARTNERS, 867 BOYLSTON ST., 5TH FLOOR, #1361, BOSTON MA 02116
Thomas B Ellis	director, 10 percent owner	867 BOYLSTON STREET, 5TH FLOOR, #1361, BOSTON MA 02116
North Run Advisors, Llc	10 percent owner	62 WALNUT STREET, WELLESLEY MA 02481
North Run Capital, Lp	10 percent owner	867 BOYLSTON STREET, 5TH FLOOR, #1361, BOSTON MA 02116
Staab Thomas R Ii	officer: Chief Financial Officer	C/O INSPIRE PHARMACEUTICALS, INC., 4222 EMPEROR BLVD., SUITE 200, DURHAM NC 27703
Kendra Wong	officer: Principal Accounting Officer	C/O LENSAR, INC., 2800 DISCOVERY DRIVE, SUITE 100, ORLANDO FL 32826
Elizabeth G. O'farrell	director	932 SOUTHWOOD BLVD., INCLINE VILLAGE NV 89451
Alan B. Connaughton	officer: Chief Operating Officer	C/O LENSAR, INC., 2800 DISCOVERY DRIVE, ORLANDO FL 32826
Nicholas T Curtis	director, officer: Chief Executive Officer	C/O STAAR SURGICAL CO, 1911 WALKER AVE, MONROVIA CA 91016
Pdl Biopharma, Inc.	10 percent owner	59 DAMONTE RANCH PARKWAY, SUITE B-375, RENO NV 89521
Lindstrom Richard L Md	director	2811 WESTWOOD PL, WAYZATA MN 55391